Cogent Biosciences
COGT41.3504.50% ( +1.780 )
Cogent Biosciences (COGT)
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product c...
- Open
- 39.840
- High
- 42.110
- Low
- 39.300
- Prev. Close
- 39.570
- Volume
- 1.84M
- Turnover
- 75.34M
- Avg Price
- 41.054
- Bid/Ask Ratio
- --
- Amplitude
- 7.10%
- 52wk High
- 43.730
- Volume Ratio
- 0.67
- Turnover Ratio
- 1.21%
Cogent Biosciences Analyst Rating
View MoreForecast & Rating
Jul 20, 2026Price forecast
$54.2531.17%
Forecast & RatingStrong buy
13analysts
- Strong buy69.23%
- Buy15.38%
- Hold15.38%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jun 30 at 07:02 AM
Cogent Biosciences submits FDA NDA for bezuclastinib in advanced systemic mastocytosis
- Simplywall · Jun 29 at 11:11 PM
Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor Base
- Tip Ranks · Jun 17 at 08:35 AM
H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT)
- Unusual Whales · Jun 12 at 07:02 AM
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
- StockTitan · Jun 11 at 11:01 PM
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | COGT Stock News
- Tip Ranks · Jun 11 at 04:55 PM
Cogent Biosciences Shareholders Back Board, Governance Proposals
